CelluliteNCT05358847
Treatment for Cellulite Appearance
A study testing Sofwave in people with Cellulite, run by Sofwave Medical LTD at 4 sites in United States.
Trial summary
Open-label, non-randomized, prospective, multi-center, self-controlled clinical study with masked evaluation. Read more about this study
- Who is it for?
- Ages 18 to 60 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Cellulite
- What is being tested?
- Sofwave
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 69 participants
- Where
- 4 sitesUnited States
- Study dates
- 21 Nov 2021to 1 Mar 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy female subjects > 18 years of age and < 60 years of age
- Not pregnant or lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide) or abstinence.
- Have visible cellulite in the upper thigh and/or buttock areas.
- Seeking treatment of cellulite in the upper thigh and/or buttock areas.
- Stable weight nominally ±5% for at least past 6 months
- Subject agrees to maintain her weight (i.e., within 5% of total body weight) by not making any major changes in their diet or exercise routine during the study course.
Show all 12Show fewer
- Subject did not undergo invasive or energy-based cellulite treatments (liposuction, subcision, RF, laser, ESWT, etc.) for the prior 12 months.
- Subject did not use topical based cellulite treatments for prior 6 months and will not use during the trial (except for the study related procedures)
- Subject agrees not to undergo any other cellulite treatments for a period of 6 months following Sofwave treatment
- Willing to have photographs of the treated areas. Agree for de-identified study images to be used in evaluations, publications, and presentations.
- Able and willing to comply with all visits, treatments and evaluations schedules and requirements.
- Able to understand and provide written Informed Consent.
Who cannot join
- Pregnant or planning to become pregnant during the duration of the study, having given birth less than 3 months ago, and/or breast feeding
- Currently heavy smoker or has history of heavy smoking (25 cigarettes per day or more) in past 10 years
- BMI>=30kg/m2
- Non-stable weight nominally ±5% for at least past 6 months
- Currently taking or has taken diet pills or weight control supplements within the past month
- History of severe migraine tendency
Show all 30Show fewer
- History of Epileptic seizures
- History of chronic drug or alcohol abuse
- History of coagulopathy(ies) and/or on anticoagulant medication
- History of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising
- Medical disorder that would hinder the wound healing or immune response (such as blood disorder, inflammatory disease, etc.)
- Active implanted device such as a pacemaker, defibrillator, cochlear implants, nerve/brain stimulators or drug delivery system
- Known allergy to lidocaine or epinephrine or antibiotics
- Active malignancy or history of malignancy in the past 5 years
- Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders (i.e. any disease state that in the opinion of the investigator may interfere with the anesthesia, treatment, or healing process)
- History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications
- Suffering from hormonal imbalance, whether related to thyroid, pituitary, or androgen
- History of significant lymphatic drainage problems
- History of epidermal or dermal disorders (particularly involving collagen or microvascularity), including collagen vascular disease or vasculitic disorders.
- Skin disorders (skin infections or rashes, extensive scarring, psoriasis, etc.) in the treatment area.
- Severe solar elastosis on the intended to treat area.
- Significant scarring, atrophic scars in the area to be treated, or has a history of atrophic scars or keloids or prone to bruising
- Tattoo or former tattoo at or near treatment area
- Presence of an implant (metal or plastic) in or adjacent to area of intended treatment (vascular stent, or implants in the hips, knees, etc)
- Inability to understand the protocol or to give informed consent
- On-going use of psychiatric medication
- Unable or unwilling to comply with the study requirements and procedures
- Unwilling to have research photos taken of treatment areas
- Currently enrolled in a clinical study of any other unapproved investigational drug or device
- Any other condition that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject
Trial locations and contacts
4 sites in 1 country.
United States4 sites
Dermatology, Laser & Vein Specialists of the Carolinas
Charlotte, North Carolina, 28207
UnionDerm
New York, New York, 10003
Laser & Skin Surgery Center of New York®
New York, New York, 10016
Laser & Skin Surgery Center of Northern California
Sacramento, California, 95816
About this study
Official title: Safety and Efficacy of Sofwave Treatment for Improvement of Cellulite Appearance
Open-label, non-randomized, prospective, multi-center, self-controlled clinical study with masked evaluation.
Read the detailed description
Eligible patients will receive 2 treatments (4-6 weeks apart) on one side (right or left) of the lateral/ posterior upper thigh / buttocks using Sofwave System.
Treatment may be administered after the enrollment and screening at the first visit, or it may occur later following the enrollment and screening activities based on site scheduling availabilities.
All patients will return to the clinic for one follow up visits at 3 months ± 3 weeks post last treatment (FU1). Optionally, additional follow-up visit will be conducted 6 (± 4 weeks) months following end of treatment (FU2).
Methodology described in the protocol to evaluate efficacy and safety of treatments will be carried out at each visit at the clinic.
- Conditions
- Cellulite
- Being tested
- Sofwave
- Keywords
- upper thigh, buttock, skin laxity
- Medical subject headings
- Cellulite, Cutis Laxa
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SofwaveDevice
Also called SUPERB
The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
| Study group | Role | What they receive |
|---|---|---|
| Cellulite | Experimental | Not described Receives: Device: Sofwave |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of improvement in the appearance of cellulite on the upper thigh/buttock area
following Sofwave treatments based on 6 points simplified Cellulite Severity Scale (CSS), as evaluated by independent masked reviewers.
Measured: 3 months post treatment follow-up visit.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 May 2022
- Study start21 Nov 2021
- Primary completion1 Mar 2023
- Study completion1 Mar 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CelluliteStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 69 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sofwave Medical LTD
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05358847
- Sponsor's protocol ID
- Sofwave08
- Status last verified
- Apr 2023
- First submitted
- 27 Apr 2022
- Last updated
- 18 Nov 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 18 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety and Efficacy of Sofwave Treatment for Improvement of Cellulite Appearance
- ClinicalTrials.gov ID
- NCT05358847
- Acronym / sponsor ID
- Sofwave08
- Conditions
- Cellulite
- Keywords
- upper thigh, buttock, skin laxity
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 69 participants (actual)
- Lead sponsor
- Sofwave Medical LTDIndustry (pharma, biotech, devices)
- Study start
- 21 Nov 2021 (actual)
- Primary completion
- 1 Mar 2023 (actual)
- Study completion
- 1 Mar 2023 (actual)
- First posted
- 3 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Open-label, non-randomized, prospective, multi-center, self-controlled clinical study with masked evaluation.
Detailed description
Eligible patients will receive 2 treatments (4-6 weeks apart) on one side (right or left) of the lateral/ posterior upper thigh / buttocks using Sofwave System.
Treatment may be administered after the enrollment and screening at the first visit, or it may occur later following the enrollment and screening activities based on site scheduling availabilities.
All patients will return to the clinic for one follow up visits at 3 months ± 3 weeks post last treatment (FU1). Optionally, additional follow-up visit will be conducted 6 (± 4 weeks) months following end of treatment (FU2).
Methodology described in the protocol to evaluate efficacy and safety of treatments will be carried out at each visit at the clinic.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cellulite | Experimental | Device: Sofwave |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (12 listed)
- Healthy female subjects > 18 years of age and < 60 years of age
- Not pregnant or lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide) or abstinence.
- Have visible cellulite in the upper thigh and/or buttock areas.
- Seeking treatment of cellulite in the upper thigh and/or buttock areas.
- Stable weight nominally ±5% for at least past 6 months
Key exclusion criteria (30 listed)
- Pregnant or planning to become pregnant during the duration of the study, having given birth less than 3 months ago, and/or breast feeding
- Currently heavy smoker or has history of heavy smoking (25 cigarettes per day or more) in past 10 years
- BMI>=30kg/m2
- Non-stable weight nominally ±5% for at least past 6 months
- Currently taking or has taken diet pills or weight control supplements within the past month
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SofwaveAlso: SUPERBThe Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues. | Device | Cellulite |
Primary outcome
Rate of improvement in the appearance of cellulite on the upper thigh/buttock area
Time frame: 3 months post treatment follow-up visit.
following Sofwave treatments based on 6 points simplified Cellulite Severity Scale (CSS), as evaluated by independent masked reviewers.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Cellulite
Not yet recruiting
Pilot Study of Naringenin Beta Carotene Cream for Local Fat Reduction (SCULPT)
Thigh Cellulite
Active, not recruiting
Cyrolipolysis vs Cyrolipolysis and Subcision for Cellulite
Cellulite
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Sofwave in people with Cellulite, run by Sofwave Medical LTD at 4 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of improvement in the appearance of cellulite on the upper thigh/buttock area (time frame: 3 months post treatment follow-up visit.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2023.